Baxter International (BAX) Expected to Announce Earnings on Thursday

Baxter International (NYSE:BAX) will likely be posting its Q2 2026 results before the market opens on Thursday, July 30th. Analysts expect the company to post earnings of $0.36 per share and revenue of $2.7927 billion for the quarter. Individuals can check the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Thursday, July 30, 2026 at 8:30 AM ET.

Baxter International (NYSE:BAX) last posted its quarterly earnings results on Thursday, April 30th. The medical instruments supplier reported $0.36 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.31 by $0.05. The firm had revenue of $2.70 billion during the quarter, compared to analyst estimates of $2.62 billion. Baxter International had a negative net margin of 9.70% and a positive return on equity of 16.15%. The company’s quarterly revenue was up 2.9% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.62 earnings per share. On average, analysts expect Baxter International to post $2 EPS for the current fiscal year and $2 EPS for the next fiscal year.

Baxter International Stock Up 4.4%

Shares of BAX opened at $23.38 on Tuesday. The company has a quick ratio of 1.23, a current ratio of 1.85 and a debt-to-equity ratio of 1.43. The company has a 50-day moving average price of $20.81 and a two-hundred day moving average price of $19.46. The stock has a market cap of $12.08 billion, a price-to-earnings ratio of -10.98, a P/E/G ratio of 3.62 and a beta of 0.62. Baxter International has a 12 month low of $15.73 and a 12 month high of $29.35.

Baxter International Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Wednesday, July 1st. Stockholders of record on Friday, May 29th were issued a $0.01 dividend. The ex-dividend date of this dividend was Friday, May 29th. This represents a $0.04 dividend on an annualized basis and a dividend yield of 0.2%. Baxter International’s dividend payout ratio is presently -1.88%.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the stock. Jump Financial LLC boosted its position in Baxter International by 5.7% in the 4th quarter. Jump Financial LLC now owns 15,968 shares of the medical instruments supplier’s stock valued at $305,000 after buying an additional 854 shares during the last quarter. Public Employees Retirement System of Ohio raised its holdings in Baxter International by 0.6% during the 3rd quarter. Public Employees Retirement System of Ohio now owns 160,033 shares of the medical instruments supplier’s stock worth $3,644,000 after purchasing an additional 993 shares during the last quarter. Imprint Wealth LLC acquired a new position in Baxter International during the 3rd quarter valued at about $27,000. MUFG Securities EMEA plc acquired a new position in Baxter International in the second quarter valued at approximately $46,000. Finally, Baird Financial Group Inc. grew its holdings in Baxter International by 3.2% during the 2nd quarter. Baird Financial Group Inc. now owns 52,436 shares of the medical instruments supplier’s stock worth $1,588,000 after acquiring an additional 1,604 shares during the period. Institutional investors own 90.19% of the company’s stock.

Analyst Ratings Changes

Several analysts recently commented on BAX shares. Zacks Research lowered Baxter International from a “hold” rating to a “strong sell” rating in a research note on Monday, July 13th. Weiss Ratings raised shares of Baxter International from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, July 15th. Evercore dropped their price objective on shares of Baxter International from $23.00 to $22.00 and set an “outperform” rating for the company in a report on Monday, April 6th. Stifel Nicolaus cut their target price on shares of Baxter International from $20.00 to $19.00 in a research note on Friday, May 1st. Finally, Barclays boosted their target price on Baxter International from $25.00 to $27.00 and gave the stock an “overweight” rating in a report on Friday, May 1st. Two investment analysts have rated the stock with a Buy rating, seven have given a Hold rating and four have assigned a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Reduce” and a consensus target price of $20.27.

About Baxter International

Baxter International Inc is a global healthcare company that develops, manufactures and markets a broad portfolio of medical products, pharmaceutical therapies and biotechnology-based solutions. The company’s primary business activities are organized around renal care, medication delivery, acute therapies, pharmacy automation, surgical care and biotechnology. Baxter’s offerings are designed to support patient care in hospitals, dialysis centers, nursing homes and other healthcare facilities worldwide.

In the renal care segment, Baxter provides hemodialysis and peritoneal dialysis systems, water treatment equipment and related disposables, including dialyzers, bloodlines and catheters.